CD274 and non-small cell lung carcinoma: 9 FDA drug approvals related to a specific PD-L1 threshold and companion diagnostic in various cancers, such as bladder cancer, NSCLC, TNBC, cervical cancer, and gastric/gastroesophageal junction cancer [257].